logo

For the Inventor, By the Inventor

Chorleywood, United Kingdom

Andrew David Goodearl

This inventor holds 20 USPTO granted patents, primarily in Glial Growth Factors. Top assignees: Ludwig Institute for Cancer Research Limited, Acorda Therapeutics, Inc., Cambridge Neuroscience, Inc.. Active years: 1996-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew David Goodearl. Retrieved from https://idiyas.com/inventor/andrew-david-goodearl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 20

% Patents Active = 90.0

Average Co-Inventor Count = 6.6

ph-index = 7

Forward Citations = 207(Granted Patents)


Location History:

  • Hertfordshire, GB (1997)
  • Chorleywood, GB (1996 - 2011)

Company Filing History:

goldMedal16 out of 530 
 
Ludwig Institute for Cancer Research Limited
 patents
silverMedal8 out of 90 
 
Acorda Therapeutics, Inc.
 patents
bronzeMedal7 out of 43 
 
Cambridge Neuroscience, Inc.
 patents
4. 1 out of 1 
 
Cambridge Neuroscience Research Inc.
 patent
5. 1 out of 1 
 
Ludwig Institute for Cancer Research and Cambridge Neuroscience
 patent
6. 3 out of 834,601 
Other
 patents
where one patent can have more than one assignee

Years Active: 1996-2011

Loading Chart...
Areas of Expertise:
Glial Mitogenic Factors
Nervous System Treatment
Multiple Sclerosis
Mitogenesis
Polypeptides
Secretable Factors
Schwann Cell
Pathophysiological Conditions
DNA Encoding
Preparation Methods
Growth Factor Applications
Cell Stimulation
20 patents (USPTO):Explore Patents
1. 7968678 - Glial mitogenic factors, their preparation and use (2011-06-28),
2. 7541338 - Glial mitogenic factors, their preparation and use (2009-06-02),
3. 7319019 - Glial mitogenic factors lacking an N-terminal signal sequence (2008-01-15),
4. 7285531 - Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor (2007-10-23),
5. 7192915 - Methods for treating multiple sclerosis with GGF-related polypeptides (2007-03-20),
6. 7135456 - Glial mitogenic factors, their preparation and use (2006-11-14),
7. 7094749 - Glial mitogenic factors, their preparation and use (2006-08-22),
8. 6972280 - Glial mitogenic factors, their preparation and use (2005-12-06),
9. 6232286 - Methods of stimulating mitogenesis in glial cells using glial mitogenic factors (2001-05-15),
10. 6204241 - Method for treating nervous system pathophysiologies using glial growth factors (2001-03-20),
11. 6194377 - Methods for treating nervous system pathophysiologies using glial growth factors (2001-02-27),
12. 6147190 - Glial mitogenic factors, their preparation and use (2000-11-14),
13. 5854220 - Glial mitogenic factors, their preparation and use (1998-12-29),
14. 5792849 - Glial mitogenic factors, their preparation and use (1998-08-11),
15. 5716930 - Glial growth factors (1998-02-10),

As a specialist in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide you with an article about inventor Andrew David Goodearl.

Title: The Innovations of Andrew David Goodearl

Introduction:

Andrew David Goodearl, a talented inventor based in Chorleywood, GB, has made significant contributions in the field of glial cell research. With 20 patents to his name, Goodearl has demonstrated a keen interest in advancing treatments for diseases involving glial cells.

Latest Patents:

One of his latest patents involves "Glial Mitogenic Factors, Their Preparation, and Use." This patent focuses on the characterization and purification of DNA encoding polypeptides that stimulate glial cell mitogenesis, particularly Schwann cells, for the treatment of glial cell tumors. The patent also covers methods for synthesizing, purifying, and testing these polypeptides for therapeutic and diagnostic purposes.

Career Highlights:

Throughout his career, Goodearl has worked with esteemed organizations such as the Ludwig Institute for Cancer Research Limited and Acorda Therapeutics, Inc. His dedication to research and development has led to groundbreaking discoveries in the treatment of diseases related to glial cells.

Collaborations:

Goodearl has collaborated closely with fellow researchers, including Paul Stroobant and Michael Derek Waterfield. Their combined efforts have furthered the understanding of glial cell biology and paved the way for innovative treatment options.

Conclusion:

In conclusion, Andrew David Goodearl stands as a prominent figure in the field of glial cell research, with a remarkable portfolio of patents that have the potential to revolutionize the treatment of glial cell-related diseases. His collaborations and career highlights underscore his commitment to driving innovation in the medical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…